Home				Neurodegenerative Diseases Tx/Dx CI - Y2006 week 43
DATE	SOURCE	OTHER PARTY INVOLVED	INDICATION(S)	HEADLINES - CLICK TO VIEW FULL RELEASE
10/26/06	Diamyd Medical (SE)	Neurologix (US)	Parkinson	Year End Report for Diamyd Medical AB (publ)
10/26/06	Millennium Pharmaceuticals (US)		Multiple sclerosis	Millennium Achieves Non-GAAP Profitability and Reduces GAAP Net Loss for Third Consecutive Quarter(1)
10/26/06	MultiCell Technologies (US)		Multiple sclerosis	MultiCell Technologies Recaps New Investor Conference Call Discussing Recent Drug Development Initiatives and Strengthened IP Portfolio
10/26/06	The Immune Response (US)	Spelman Research (US)	Multiple sclerosis	Spelman Research Initiates Coverage of The Immune Response Corporation With Price Target of $0.059 Per Share
10/24/06	BioMS Medical (CA)		Multiple sclerosis	BioMS Medical expands pivotal multiple sclerosis trial into the Baltic States
10/24/06	MultiCell Technologies (US)		Multiple sclerosis	MultiCell Establishes Clinical Development Team to Lead UK Phase IIb Human Clinical Trials for MCT-125 for the Treatment of Fatigue in MS Patients
10/23/06	Amgen (US)		Alzheimer	Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04 GAAP Earnings Per Share…
10/23/06	Medivir (SE)		Multiple sclerosis	Medivir, Interim Report, 1 January - 30 September 2006
10/23/06	NeuroSearch (DK)	A. Carlsson Research (SE)	Huntington	NeuroSearch closes acquisition of A. Carlsson Research AB and adjusts its outlook for the full year and warrant programmes
10/23/06	Santhera Pharmaceuticals (CH)		Parkinson	Santhera announces an Initial Public Offering and subsequent listing on the SWX Swiss Exchange